Statement of Retraction: Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology(Journal of Obstetrics and Gynaecology, (2008), 28, (3), (280-284), 10.1080/01443610802042688);Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology

Journal of Obstetrics and Gynaecology

Volumn 28, Issue 3, 2008, Pages 280-284

  Badawy, A M ^a   Khiary, M ^a   Sherif, L S ^a   Hassan, M ^a   Ragab, A ^a   Abdelall, I ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Low molecular weight heparin; Recurrent abortion

Indexed keywords

ENOXAPARIN; FOLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; STEROID;

ADULT; ARTICLE; BIRTH WEIGHT; BLEEDING; CESAREAN SECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECCHYMOSIS; ECHOGRAPHY; FEMALE; FETAL WELL BEING; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; INCIDENCE; INJECTION SITE REACTION; INTRAPARTUM HEMORRHAGE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY TERMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RECURRENT ABORTION; SKIN MANIFESTATION; SOLUTIO PLACENTAE; SURGICAL WOUND; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 45749103279     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.1080/01443615.2022.2144516     Document Type: Erratum

References (30)

1. ACOG. 2001. Management of recurrent pregnancy loss. Practice Bulletin 24:1-12.
2. Aoki K, Kajiura S, Metsumoto Y, Ogasawara M, Okada S, Yagami Y. 1995. Preconceptual natural killer-cells activity as a predictor of miscarriage. Lancet 345:1340-1342.
3. Beaufils M, Donsimoni R, Uzan S, Colau JL. 1985. Prevention of preeclampsia by early antiplatelet therapy. Lancet 1:840-842.
4. Branch DW, Khamashta MA. 2003. Antiphospholipid syndrome: obstetric diagnosis, management and controversies. Obstetrics and Gynecology 101:1333-1344.
5. Clifford K, Rai R, Regan L. 1997. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Human Reproduction 12:387-389.
6. Di Simone N, Ferrazzani S, Castellani R, De Carolis S, Mancuso S, Caruso A. 1997. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Human Reproduction 12:2061-2065.
7. Girardi G, Redecha P, Salmon JE. 2004. A potential mechanism for therapeutics efficacy of heparin in antiphospholipid antibodies-induced pregnancy loss - inhibition of complement. Nature Medicine 10:1222-1226.
8. Farquharson RG, Jauniaux E, Exalto N. 2005. ESHRE Special Interest Group for Early Pregnancy (SIGEP). Updated and revised nomenclature for description of early pregnancy events. Human Reproduction 20:3008-3011.
9. Fiedler K, Würfel W. 2004. Effectivity of heparin in assisted reproduction. European Journal of Medical Research 9:207-214.
10. Hamatani T, Daikoku T, Wang H, Matsumoto H, Carter MG, Ko MS et al. 2004. Global gene expression analysis identifies molecular pathways distinguishing blastocyst dormancy and activation. Proceedings of the National Academy of Science USA 101:10326-10331.
11. Lash GE, Warren AY, Underwood S, Baker PN. 2003. Vascular endothelial growth factor is a chemoattractant for trophoblast cells. Placenta 24:549-556.
12. Leach RE, Kilburn B, Wang J, Liu Z, Romero R, Armant DR. 2004. Heparin-binding EGF-like growth factor regulates human extravillous cytotrophoblast development during conversion to the invasive phenotype. Developmental Biology 266:223-237.
13. Lockwood CJ. 2002. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstetrics and Gynecology 99:333-341.
14. Di Nisio M, Peters LW, Middeldorp S. 2007. Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome. Cochrane Database of Systematic Reviews Issue 3.
15. Manduteanu I, Voinea M, Capraru M, Dragomir E, Simionescu M. 2002. A novel attribute of enoxaparin: inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules. Pharmacology 65:32-37.
16. Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa M. 2000. Mutations in coagulation factors in women with unexplained late fetal loss. New England Journal of Medicine 343:1015-1018.
17. Pattison NS, Chamley LW, Birsdall M, Zanderigo AM, Liddell HS, McDougall J. 2000. Does aspirin has a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. American Journal of Obstetrics and Gynecology 183:1008-1012.
18. Rai RS, Regan L, Clifford K, Pickering W, Dave M, Mackie I. 1995. Antiphospholipid antibodies and B2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Human Reproduction 10:2001-2005.
19. Rai R, Cohen H, Dave M, Regan L. 1997. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies. British Medical Journal 314:253-257.
20. Rey E, Kahn S, David R, Shrier MI. 2003. Thrombophilia and fetal loss. A meta-analysis. Lancet 361:901-908.
21. Ridker PM, Miletich PW, Buring JE, Ariyo AA, Price DT, Manson JE. 1998. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Annals of Internal Medicine 128:1000-1003.
22. Riyazi N, Leeda M, de Vries JIP, Huijgens PC, van Geijn HP, Dekker GA. 1998. Low-molecular-weight heparin with aspirin in women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. European Journal of Obstetrics, Gynecology and Reproductive Biology 80:49-54.
23. Roque H, Paidas M, Rebarber A, Kahn S, Kuczynski E, Lockwood C. 2001. There is no association between maternal thrombophilia and recurrent first trimester loss. American Journal of Obstetrics and Gynecology 184:515-519.
24. Rops AL, Van der Vlag J, Lensen JF, Wijnhoven TJ, van den Heuvel LP, van Kuppevelt TH et al. 2004. Heparan sulfate proteoglycans in glomerular inflammation. Kidney International 65:768-785.
25. RCOG. 2003. Investigation and treatment of couples with recurrent miscarriage. Guideline No. 17. London: RCOG Press.
26. Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A et al. 1996. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thrombosis and Haemostasis 75:387-388.
27. Seligshon U, Lubetsky A. 2001. Genetic susceptibility to venous thrombosis. New England Journal of Medicine 344:1222-1231.
28. Van Horn, JT, Craven C, Ward K, Branch DW, Silver RM. 2004. Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta 25:642-648.
29. Walport MJ. 2001. Complement. New England Journal of Medicine 344:1058-1066.
30. Wilson WA, Gharavi AE, Koile T, Lockshin MD, Branch DW, Piette JC. 1999. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report on an international workshop. Arthritis and Rheumatism 42:1309-1311.